Literature DB >> 32171859

A Modified Murine Abdominal Aortic Aneurysm Rupture Model using Elastase Perfusion and Angiotensin II Infusion.

Jianing Yue1, Li Yin2, Jian Shen3, Zhenjie Liu4.   

Abstract

OBJECTIVE: To establish a murine abdominal aortic aneurysm rupture model using a combination of elastase treatment and angiotensin II infusion.
METHODS: The murine abdominal aorta was treated with elastase. Angiotensin II was infused at a dose of 1000 ng/kg/min via an osmotic pump placed subcutaneously. A saline osmotic pump was used as the control. The aortas were harvested from the mice 4 weeks later, or earlier if mice died. The abdominal aorta was inspected using ultrasound and microscopy for aneurysm formation and/or signs of rupture. The aneurysm outcome was measured using aortic expansion and proinflammatory cytokine expression. It was also compared with the established conventional elastase perfusion and angiotensin II infusion abdominal aortic aneurysm models.
RESULTS: By day 28 after surgery, all abdominal aortas of mice treated in the modified group had dilated and progressed to abdominal aortic aneurysms with 60% ruptured aneurysms, whereas none of the control aortas treated with saline became aneurysmal. In mice treated with elastase solution alone, 100% developed aneurysms and only one had a ruptured aneurysm. In mice given angiotensin II infusion alone, 37.5% developed aneurysms and none had a ruptured aneurysm. Histological examination of the modified murine abdominal aortic aneurysm rupture model was identical to those observed in the conventional elastase model. Quantitative polymerase chain reaction analysis revealed similarly increased levels of proinflammatory cytokines.
CONCLUSIONS: We modified two current murine abdominal aortic aneurysm models to develop a murine abdominal aortic aneurysm model with consistent aneurysm formation and high rupture incidence, which can be used for studying abdominal aortic aneurysm rupture and treatment.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abdominal aortic aneurysm rupture;; Angiotensin II;; Elastase;; Murine model;

Year:  2020        PMID: 32171859     DOI: 10.1016/j.avsg.2020.03.002

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  6 in total

1.  Akkermansia muciniphila Alters Gut Microbiota and Immune System to Improve Cardiovascular Diseases in Murine Model.

Authors:  Xin He; Yang Bai; Haiyang Zhou; Kemin Wu
Journal:  Front Microbiol       Date:  2022-06-14       Impact factor: 6.064

2.  The role and mechanism of epidermal growth factor receptor in hemodynamic induction of abdominal aortic aneurysm formation.

Authors:  Leiting Liu; Honglin Wang; Xi Chen; Yangcheng Zhao
Journal:  Ann Transl Med       Date:  2022-09

3.  Characterization of a murine model of endothelial dysfunction induced by chronic intraperitoneal administration of angiotensin II.

Authors:  Celeste Trejo-Moreno; Enrique Jiménez-Ferrer; Gabriela Castro-Martínez; Marisol Méndez-Martínez; María Angélica Santana; Gerardo Arrellín-Rosas; José Pedraza-Chaverri; Omar Noel Medina-Campos; Beatriz Hernández-Téllez; Oscar Ramírez-Pliego; Maribel Herrera-Ruiz; Jacquelynne Cervantes-Torres; Zimri Aziel Alvarado-Ojeda; Alejandro Costet-Mejía; Gladis Fragoso; Gabriela Rosas-Salgado
Journal:  Sci Rep       Date:  2021-10-27       Impact factor: 4.379

4.  Establishment of a New Abdominal Aortic Aneurysm Model in Rats by a Retroperitoneal Approach.

Authors:  Jun-Xing Zhu; Quan-Qiao Tang; Can Zhou; Xing-Chi Shi; Si-Yi Yi; Ying Yang
Journal:  Front Cardiovasc Med       Date:  2022-02-23

Review 5.  Progress in murine models of ruptured abdominal aortic aneurysm.

Authors:  Li Yin; Eric William Kent; Bowen Wang
Journal:  Front Cardiovasc Med       Date:  2022-08-12

Review 6.  Risk Factors and Mouse Models of Abdominal Aortic Aneurysm Rupture.

Authors:  Smriti Murali Krishna; Susan K Morton; Jiaze Li; Jonathan Golledge
Journal:  Int J Mol Sci       Date:  2020-09-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.